ClarityVesting

Sign in Get free access

Healthcare

Stock Analysis · Aurinia Pharmaceuticals Inc (AUPH)

Aurinia Pharmaceuticals is a profitable biotech built around LUPKYNIS for lupus nephritis. Sales growth, rising cash generation, and low debt have transformed its profile, while a modest earnings multiple keeps attention on how durable that progress can be.

Stock Analysis · Fagron NV (ARSUF)

Fagron supplies the ingredients, formulations, and outsourced services behind customized medicines. Its appeal comes from steady healthcare demand, a strong niche position in compounding, expanding U.S. sterile capacity, and a record of growing revenue with solid margins.

Stock Analysis · ArriVent BioPharma Inc (AVBP)

ArriVent BioPharma is a clinical-stage cancer drug developer centered on firmonertinib for EGFR-mutated lung cancer. The company combines a focused pipeline, a large market opportunity, and minimal debt, making clinical progress the key force behind its long-term outlook.

Stock Analysis · Astrana Health Inc (ASTH)

Astrana Health builds physician-centered, value-based care networks that manage patient populations at scale. Rapid revenue expansion, a sharp rise in free cash flow, and exposure to a growing healthcare model make its progress worth a closer look.

Stock Analysis · Alphatec Holdings Inc (ATEC)

Alphatec is a focused spine-surgery device company building an integrated platform of implants, access tools, biologics, and enabling technology. Revenue growth has been strong and cash flow is improving, making its scale-up and margin transition worth a closer look.

Stock Analysis · Ascentage Pharma Group International (ASPHF)

Ascentage Pharma is building a targeted cancer drug portfolio led by olverembatinib and a broader oncology pipeline. Strong revenue growth and partnership activity make it notable, while the next stage depends on turning clinical progress into broader commercialization.

Stock Analysis · agilon health Inc (AGL)

agilon health helps primary care groups manage senior patients under value-based care contracts. The company operates in a growing healthcare niche, and recent momentum reflects renewed interest in its ability to scale physician partnerships and improve cost control.